Development of responder definitions for fibromyalgia clinical trials
dc.contributor.author | Arnold, Lesley M. | en_US |
dc.contributor.author | Williams, David A. | en_US |
dc.contributor.author | Hudson, James I. | en_US |
dc.contributor.author | Martin, Susan A. | en_US |
dc.contributor.author | Clauw, Daniel J. | en_US |
dc.contributor.author | Crofford, Leslie J. | en_US |
dc.contributor.author | Wang, Fujun | en_US |
dc.contributor.author | Emir, Birol | en_US |
dc.contributor.author | Lai, Chinglin | en_US |
dc.contributor.author | Zablocki, Rong | en_US |
dc.contributor.author | Mease, Philip J. | en_US |
dc.date.accessioned | 2012-03-16T15:58:29Z | |
dc.date.available | 2013-05-01T17:24:41Z | en_US |
dc.date.issued | 2012-03 | en_US |
dc.identifier.citation | Arnold, Lesley M.; Williams, David A.; Hudson, James I.; Martin, Susan A.; Clauw, Daniel J.; Crofford, Leslie J.; Wang, Fujun; Emir, Birol; Lai, Chinglin; Zablocki, Rong; Mease, Philip J. (2012). "Development of responder definitions for fibromyalgia clinical trials." Arthritis & Rheumatism 64(3): 885-894. <http://hdl.handle.net/2027.42/90281> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/90281 | |
dc.description.abstract | Objective To develop responder definitions for fibromyalgia (FM) clinical trials using key symptom and function domains. Methods Twenty‐four candidate responder definitions were developed by expert consensus and were evaluated in 12 randomized, placebo‐controlled trials of 4 medications for the treatment of FM. For each definition, the treatment effects of the medication compared with placebo were analyzed using Cochran‐Mantel‐Haenszel tests or chi‐square tests. A meta‐analysis of the pooled results for the 4 medications established risk ratios to determine the definitions that best favored medication over placebo. Results Two definitions performed best in the analyses. Both definitions included ≥30% reduction in pain and ≥10% improvement in physical function. The definitions differed in that one (≥30% improvement in FM [FM30] short version) included ≥30% improvement in sleep or fatigue, and the other (FM30 long version) required ≥30% improvement in 2 of the following symptoms: sleep, fatigue, depression, anxiety, or cognition. In the analysis of both versions, the response rate was ≥15% for each medication and was significantly greater compared with placebo. The risk ratio favoring drug over placebo in the pooled analysis for FM30 version 3 (short version) was 1.50 (95% confidence interval [95% CI] 1.24–1.82; P ≤ 0.0001); the risk ratio for FM30 version 6 (long version) was 1.60 (95% CI 1.31–1.96; P ≤ 0.00001). Conclusion Among the 24 responder definitions tested, 2 were identified as most sensitive in identifying response to treatment. The identification of responder definitions for FM clinical trials that include assessments of key symptom and function domains may improve the sensitivity of clinical trials to identify meaningful improvements, leading to improved management of FM. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.title | Development of responder definitions for fibromyalgia clinical trials | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan Medical School, Ann Arbor | en_US |
dc.contributor.affiliationother | Jazz Pharmaceuticals, Palo Alto, California | en_US |
dc.contributor.affiliationother | Cypress Bioscience, San Diego, California | en_US |
dc.contributor.affiliationother | Women's Health Research Program, University of Cincinnati College of Medicine, Medical Arts Building, 222 Piedmont Avenue, Suite 8200, Mail Location 665S, Cincinnati, OH 45219 | en_US |
dc.contributor.affiliationother | Swedish Medical Center and University of Washington, Seattle | en_US |
dc.contributor.affiliationother | University of Cincinnati College of Medicine, Cincinnati, Ohio | en_US |
dc.contributor.affiliationother | Harvard Medical School, Boston, Massachusetts, and McLean Hospital, Belmont, Massachusetts | en_US |
dc.contributor.affiliationother | RTI Health Solutions, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | University of Kentucky, Lexington | en_US |
dc.contributor.affiliationother | Eli Lilly, Indianapolis, Indiana | en_US |
dc.contributor.affiliationother | Pfizer, New York, New York | en_US |
dc.identifier.pmid | 21953205 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/90281/1/33360_ftp.pdf | |
dc.identifier.doi | 10.1002/art.33360 | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.identifier.citedreference | Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995; 39: 315 – 25. | en_US |
dc.identifier.citedreference | Arnold LM. Biology and therapy of fibromyalgia: new therapies in fibromyalgia. Arthritis Res Ther 2006; 8: 212. | en_US |
dc.identifier.citedreference | Witter J, Simon LS, Dianne R. Are means meaningless? The application of individual responder analysis to analgesic drug development. APS Bull 2003; 13: 4 – 7. | en_US |
dc.identifier.citedreference | Boers M, Brooks P, Simon LS, Strand V, Tugwell P. OMERACT: an international initiative to improve outcome measurement in rheumatology. Clin Exp Rheumatol 2005; 23: S10 – 3. | en_US |
dc.identifier.citedreference | Arnold LM, Crofford LJ, Mease PJ, Burgess SM, Palmer SC, Abetz L, et al. Patients' perspective on the impact of fibromyalgia. Patient Educ Couns 2008; 73: 114 – 20. | en_US |
dc.identifier.citedreference | Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, Humphrey L, et al. Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis Rheum 2008; 59: 952 – 60. | en_US |
dc.identifier.citedreference | Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, et al. Fibromyalgia syndrome: OMERACT 8 workshop. J Rheumatol 2007; 34: 1415 – 25. | en_US |
dc.identifier.citedreference | Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, et al. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol 2009; 36: 2330 – 4. | en_US |
dc.identifier.citedreference | Arnold LM, Zlateva G, Sadosky A, Emir B, Whalen E. Correlations between fibromyalgia symptom and function domains and patient global impression of change: a pooled analysis of three randomized, placebo‐controlled trials of pregabalin. Pain Med 2011; 12: 260 – 7. | en_US |
dc.identifier.citedreference | Arnold L, Martin S, Welge J. Correlations between fibromyalgia symptom and function domains and the patient global impression of improvement: an analysis of the randomized, placebo‐controlled trial of gabapentin [abstract]. Ann Rheum Dis 2010; 69 Suppl III: iii445. | en_US |
dc.identifier.citedreference | Hudson JI, Arnold LM, Bradley LA, Choy EH, Mease PJ, Wang F, et al. What makes fibromyalgia patients feel better? Correlations between patient global impression of improvement and changes in clinical symptoms and function: a pooled analysis of four randomized, placebo‐controlled trials of duloxetine. J Rheumatol 2009; 36: 2517 – 22. | en_US |
dc.identifier.citedreference | Geisser ME, Clauw DJ, Strand V, Gendreau RM, Palmer R, Williams DA. Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. Pain 2010; 149: 373 – 8. | en_US |
dc.identifier.citedreference | Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727 – 35. | en_US |
dc.identifier.citedreference | Carville SF, Choy EH. Systematic review of discriminating power of outcome measures used in clinical trials of fibromyalgia. J Rheumatol 2008; 35: 2094 – 105. | en_US |
dc.identifier.citedreference | Arnold LM, Keck PE Jr, Welge JA. Antidepressant treatment of fibromyalgia: a meta‐analysis and review. Psychosomatics 2000; 41: 104 – 13. | en_US |
dc.identifier.citedreference | O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta‐analysis. J Gen Intern Med 2000; 15: 659 – 66. | en_US |
dc.identifier.citedreference | Mease PJ, Arnold L, Wang F, Ahl J, Mohs R, Gaynor P, et al. The effect of duloxetine on cognition in patients with fibromyalgia [abstract]. Arthritis Rheum 2010; 62 Suppl: S42. | en_US |
dc.identifier.citedreference | Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23: S154 – 62. | en_US |
dc.identifier.citedreference | Ware JE Jr, Sherbourne CD. The MOS 36‐item short‐form health survey (SF‐36). I. Conceptual framework and item selection. Med Care 1992; 30: 473 – 83. | en_US |
dc.identifier.citedreference | Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A. Development and validation of a Multiple Ability Self‐Report Questionnaire. J Clin Exp Neuropsychol 1994; 16: 93 – 104. | en_US |
dc.identifier.citedreference | Belza B, Henke C, Yelin E, Epstein WV, Gilless CL. Correlations of fatigue in older adults with rheumatoid arthritis. Nurs Res 1993; 42: 93 – 9. | en_US |
dc.identifier.citedreference | Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. Measuring functioning and well‐being. Durham (NC): Duke University Press; 1992. p. 235 – 9. | en_US |
dc.identifier.citedreference | Simms RW, Felson DT, Goldenberg DL. Criteria for response to treatment in fibromyalgia [abstract]. Arthritis Rheum 1988; 31 Suppl: S100. | en_US |
dc.identifier.citedreference | Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, double‐blind clinical trial. Arthritis Rheum 1994; 37: 32 – 40. | en_US |
dc.identifier.citedreference | Simms RW, Felson DT, Goldenberg DL. Development of preliminary criteria for response to treatment in fibromyalgia syndrome. J Rheumatol 1991; 18: 1558 – 63. | en_US |
dc.identifier.citedreference | Dunkl PR, Taylor AG, McConnell GG, Alfano AP, Conaway MR. Responsiveness of fibromyalgia clinical trial outcome measures. J Rheumatol 2000; 27: 2683 – 91. | en_US |
dc.identifier.citedreference | Arnold LM, Gendreau RM, Palmer RH, Gendreau JF, Wang Y. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double‐blind, placebo‐controlled trial. Arthritis Rheum 2010; 62: 2745 – 56. | en_US |
dc.identifier.citedreference | Russell IJ, Perkins AT, Michalek JE, and the Oxybate SXB‐26 Fibromyalgia Syndrome Study Group. Sodium oxybate relieves pain and improves function in fibromyalgia syndrome: a randomized, double‐blind, placebo‐controlled, multicenter clinical trial. Arthritis Rheum 2009; 60: 299 – 309. | en_US |
dc.identifier.citedreference | Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale. Pain 2001; 94: 149 – 58. | en_US |
dc.identifier.citedreference | Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain 2008; 9: 105 – 21. | en_US |
dc.identifier.citedreference | Mease PJ, Spaeth M, Clauw DJ, Arnold LM, Bradley LA, Russell IJ, et al. Estimation of minimum clinically important difference of pain in fibromyalgia. Arthritis Care Res 2011; 63: 821 – 6. | en_US |
dc.identifier.citedreference | Ang D, Oakes TM, Jarvis J, Wang F. Correlation of overall Patient Impression of Improvement with individual items in the Fibromyalgia Impact Questionnaire [abstract]. J Pain 2010; 11 Suppl: S38. | en_US |
dc.identifier.citedreference | Cella D, Riley W, Stone A, Rothrock N, Reeve B, Yount S, et al, on behalf of the PROMIS Cooperative Group. The Patient‐Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self‐reported health outcome item banks: 2005‐2008. J Clin Epidemiol 2010; 63: 1179 – 94. | en_US |
dc.identifier.citedreference | Wolfe F, Hawley DJ, Goldenberg DL, Russell IJ, Buskila D, Neumann L. The assessment of functional impairment in fibromyalgia (FM): Rasch analyses of 5 functional scales and the development of the FM health assessment questionnaire. J Rheumatol 2000; 27: 1989 – 99. | en_US |
dc.identifier.citedreference | Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL. The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties [published erratum appears in Arthritis Res Ther 2009;11:415]. Arthritis Res Ther 2009; 11: R120. | en_US |
dc.identifier.citedreference | Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160 – 72. | en_US |
dc.identifier.citedreference | Williams DA, Clauw DJ. Understanding fibromyalgia: lessons from the broader pain research community. J Pain 2009; 10: 777 – 91. | en_US |
dc.identifier.citedreference | Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, et al. Fibromyalgia syndrome at OMERACT 9: domain construct. J Rheumatol 2009; 36: 2318 – 29. | en_US |
dc.identifier.citedreference | Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA, et al. Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. J Rheumatol 2011; 38: 1487 – 95. | en_US |
dc.identifier.citedreference | Lyrica (pregabalin) [package insert]. New York: Pfizer; 2010. | en_US |
dc.identifier.citedreference | Cymbalta (duloxetine) [package insert]. Indianapolis: Eli Lilly; 2010. | en_US |
dc.identifier.citedreference | Savella (milnacipran) [package insert]. St. Louis (MO): Forest Pharmaceuticals; 2010. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.